Association between vitiligo and smoking: A nationwide population-based study in Korea

Young Bok Lee, Ji Hyun Lee, Soo Young Lee, Dong Soo Yu, Kyung Do Han & Yong Gyu Park

No study has examined the associations between vitiligo and smoking. The purpose of this study was to investigate the incidence of vitiligo according to smoking status. We used clinical data from individuals aged over 20 years who received a health examination in the National Insurance Program between 2009 and 2012 (n = 23,503,807). We excluded individuals with pre-existing vitiligo who had ever been diagnosed with vitiligo before the index year (n = 35,710) or who were diagnosed with vitiligo within a year of the index year (n = 46,476). Newly diagnosed vitiligo was identified using claims data from baseline to date of diagnosis or December 31, 2016 (n = 22,811). The development of vitiligo was compared according to self-reported smoking status by a health examination survey. The hazard ratio of vitiligo in current smokers was 0.69 (95% confidence interval; 0.65–0.72) with a reference of never-smokers after adjustment for age, sex, regular exercise, drinking status, body mass index, diabetes mellitus, hypertension, dyslipidemia, history of stroke, and history of ischemic heart diseases. The decreased risk of vitiligo in current smokers persisted after subgroup analysis of sex and age groups. The results suggested there are suppressive effects of smoking on the development of vitiligo. Further studies are needed to evaluate the mechanism of smoking on the development of vitiligo.

Vitiligo is a common depigmentation skin disease with an estimated prevalence of 0.5–1% in the worldwide population. Vitiligo affects all skin types and ethnic groups. The highest incidence is recorded in India (up to 8.8%), followed by Mexico (4%), Japan (1.68%), and Denmark (0.38%). The annual incidence of vitiligo in South Korea was estimated at 0.12–0.13%.

Vitiligo is a multifactorial disease. It is hypothesized to be mainly caused by autoimmune factors, although genetic susceptibility, oxidative stress, and cell detachment abnormalities are also suggested etiologies. The autoimmune diseases vitiligo is associated with include autoimmune thyroid disorders, rheumatoid arthritis, adult-onset diabetes mellitus, pernicious anemia, and systemic lupus erythematosus.

Once vitiligo develops, it is difficult to treat and affects quality of life. Vitiligo can negatively affect social relations. One study showed that vitiligo has an adverse effect on patient sexuality, and it has been associated with pessimistic emotions such as shame, insecurity, and sadness. Therefore, evaluating the preventive and risk factors for vitiligo is important.

Smoking is one of the most prevalent addictive habits that affects multi-organ systems and results in several diseases. The well-known risks of smoking habits include respiratory and cardiovascular diseases. Smoking also affects the immune system and results in inflammatory reactions. Tobacco contains as many as 6,000 different components including nicotine, polycyclic aromatic hydrocarbons, tobacco glycoprotein, and some metals, many of which are considered antigenic, cytotoxic, mutagenic, and carcinogenic. The effects of smoking are considered to be harmful for human health. In terms of autoimmune skin diseases, the results have been conflicting according to various skin diseases. Smoking is known to have detrimental effects on and a positive association with psoriasis, palmoplantar pustulosis, and hidradenitis suppurativa. However, several autoimmune skin diseases, such as pemphigus vulgaris, foliaceous, and Behçet's disease, show a negative association with smoking.

We recently reported that the incidence of Behçet's disease in current smokers was significantly decreased compared to that of never-smokers in South Korea. Until now, the association between vitiligo and smoking has not been evaluated or reported.
Herein, this study aimed to investigate the incidence of vitiligo according to smoking habits using a nationwide population-based cohort design to analyze data from the National Health Insurance Research Database in Korea.

Materials and Methods

Study design and database. This study used the same dataset that was previously reported, the Korean Health Examination and the Korean National Health Insurance Service (KNHIS) claims database. Briefly, the KNHIS database contains all claims data for the KNHIS program, the Korean Medical Aid program, and all other long-term care insurance programs for 99% of the Korean population and the Korean National Health Examination database was used to select participants and obtain information on confounding variables. The health examination data included anthropometric measures, smoking status, drinking, and exercise, and self-reported medical histories. Per the methods in the previous paper, we used the linked KNHIS claims database for the same individuals to evaluate the development of vitiligo.

This nationwide, population-based retrospective cohort study used the KNHIS Claims Database (diagnoses according to the International Classification of Disease, Tenth Revision [ICD-10] code). The Institutional Review Board at the Korea Centers for Disease Control and Prevention approved the protocol (NHIS-2018-1-333). The study was also approved by the Institutional Review Board at Uijeongbu St. Mary’s Hospital, Catholic University of Korea and was conducted according to the principles of the Declaration of Helsinki. Anonymized and de-identified information were used for analyses, and therefore informed consent was not required.

Study population. The total number of individuals who underwent National Health Examinations in Korea from 2009 until 2012 was 23,503,802. The first year an individual received a health examination was considered the index year. We excluded individuals aged less than 20 years (n = 50,940) or who had missing data in the health examination survey (n = 379,035). To identify newly diagnosed vitiligo, we excluded individuals with pre-existing vitiligo who had ever been diagnosed with vitiligo before the index year (n = 35,710) or who were diagnosed with vitiligo within a year of the index year (n = 46,476). The observation began a year after the date of the baseline Health Examination in all subjects and ended when vitiligo was diagnosed or December 31, 2016. (Fig. 1)

Subgroups according to smoking status. Smoking status was obtained from a self-reported questionnaire during the health examination. Study individuals (n = 22,991,641) were divided into three groups according to smoking status; never-smoker (n = 14,345,458), ex-smoker (n = 3,042,684), and current smoker (n = 5,603,499). (Fig. 1) The amount of smoking was sub-grouped into <10 cigarettes per day, 10–19 cigarettes per day, and ≥20 cigarettes per day, and smoking duration was divided into <10 years, 10–29 years, and ≥30 years.

Comorbidities. To adjust for comorbidities, the presence of diabetes mellitus, hypertension, and dyslipidemia were defined using ICD-10 codes: diabetes mellitus (E11-14), hypertension (I10-13 and I15), and dyslipidemia (E78) with medication in KNHIS database. History of stroke or ischemic heart disease was obtained by self-reported questionnaire during the National Health examination.

Statistical analysis. We considered comorbidities including diabetes mellitus, hypertension, dyslipidemia, ischemic heart disease, and stroke as possible confounders to adjust in our analyses. Cox’s proportional hazard regression models with an age timescale were used to identify the associations between smoking status and newly diagnosed vitiligo. Hazard ratio (HR) and 95% confidence intervals (CI) for smoking status were compared to the reference (never-smoker). We performed the subgroup analyses separately for men and women and age groups (20–39 years, 40–65 years, ≥65 years). Proportional hazard assumptions were checked using log-log cumulative survival graphs and the time-dependent variable Cox model after adjustment for baseline covariates including age, sex, regular exercise, drinking status, BMI, diabetes mellitus, hypertension, dyslipidemia, history of stroke, and history of myocardial infarction, according to smoking status. All statistical analyses were performed using SAS software (ver. 9.4; SAS Institute, Cary, NC, USA).

Results

Characteristics of the study population. Among the 22,991,641 individuals, 14,345,458 were never-smokers, 3,042,684 were ex-smokers, and 5,603,499 were current smokers. The current smokers (43.34 ± 12.87 years) were younger than never-smokers (48.86 ± 14.8 years) and ex-smokers (50.11 ± 13.4 years). The percentage of men was significantly higher in ex-smokers and current smokers than in never-smokers. Drinking habits (2–3 times a month) were higher in ex-smokers and current smokers. Comorbidities including diabetes mellitus, hypertension, and dyslipidemia were highest in ex-smokers. History of previous stroke and ischemic heart disease was also higher in ex-smokers. (Table 1).

Newly diagnosed vitiligo according to smoking status. There were 16,515 newly diagnosed cases of vitiligo in never-smokers, 3,003 cases in ex-smokers, and 3,293 cases in current smokers. The incidence of newly diagnosed vitiligo was 2.63 per 10,000 person-years in never-smokers, 2.23 per 10,000 person-years in ex-smokers, and 1.35 per 10,000 person-years in current smokers. The cumulative incidence of newly diagnosed vitiligo after adjustment for covariates is shown in Fig. 2 according to smoking status. Current smokers had a significantly lower risk of vitiligo (HR 0.51, 95% CI, 0.50–0.53) compared with never-smokers. Decreased risk of newly diagnosed vitiligo in current smokers persisted after setting an age timescale in Model 1 (HR 0.56, 95% CI, 0.54–0.59) and adjustment for covariates in Model 2 (HR 0.68, 95% CI, 0.64–0.71) and Model 3 (HR 0.69, 95% CI, 0.65–0.72). Sensitivity analysis also showed decreased vitiligo risk in current smokers regardless of age or sex (Table 2).
Subgroup analysis of amount and duration of smoking. Current smokers showed a decrease in HR for newly diagnosed vitiligo in proportion to the amount of smoking compared with never-smokers; HR 0.70, 95% CI, 0.64–0.76 in current smokers who smoked less than 10 cigarettes a day, HR 0.51, 95% CI, 0.49–0.52 in current smoker who smoked 10–29 cigarettes a day, and HR 0.47, 95% CI, 0.44–0.49 in current smoker who smoked more than 30 cigarettes a day. (Table 3) Current smokers showed decreased HR for vitiligo regardless of smoking duration compared with never-smokers.

Discussion
We report a negative association between tobacco smoking and newly diagnosed vitiligo using a nation-wide cohort database. No study has reported on the incidence of vitiligo associated with smoking status. The detrimental effects of smoking have been reported for several skin diseases. Palmoplantar pustulosis is well known to be prevalent in current or ex-smokers. Psoriasis is related to smoking habits and heavier smoking is reported to increase the relative risk of psoriasis and its severity. Smoking is also considered a triggering factor in hidradenitis suppurativa and systemic lupus erythematosus. Smoking has detrimental effects on wound healing and skin aging.

In contrast, protective effects of smoking have also been reported for several skin diseases. Case-control studies report that pemphigus vulgaris and foliaceous occur less frequently in current and ex-smokers. Development of aphthous ulcers is associated with cessation of smoking. The beneficial effects of smoking on oral ulcers in Behçet's disease has been shown in several reports. Behçet's disease oral lesions appear after cessation of smoking; therefore, the beneficial effects of nicotine have been suggested. However, some studies
Another study reported that nicotine chelates ferrous ions that produce oxygen radicals and reduce the level of ROS produced by MAO. There has been a report that smokers have lower MAO activity than non-smokers.62,63 These findings suggest that smoking may modulate the production of ROS, which are known to be involved in the pathogenesis of various skin disorders.64

Table 1. Demographics of study population. (Table 4) We found that smokers had lower MAO activity compared to non-smokers, which may contribute to the observed association between smoking and vitiligo. This finding is consistent with previous reports that smoking is inversely associated with the risk of developing vitiligo.42-45

considering the harm caused by smoking and the lack of a distinct benefit for vitiligo development, we do not think smoking should be considered as a prevention or treatment option for vitiligo. We suggest investigating the mechanism of smoking in vitiligo development in vitro and in vivo to further study this relationship. Considering the harm caused by smoking and the lack of a distinct benefit for vitiligo development, we do not think smoking should be considered as a prevention or treatment option for vitiligo. We suggest investigating the mechanism of smoking in vitiligo development in vitro and in vivo to further study this relationship.

Considering the harm caused by smoking and the lack of a distinct benefit for vitiligo development, we do not think smoking should be considered as a prevention or treatment option for vitiligo. We suggest investigating the mechanism of smoking in vitiligo development in vitro and in vivo to further study this relationship.

There were several limitations in our study. First, the genetic susceptibility of individuals or family history of vitiligo was not evaluated. Second, causai links between smoking and vitiligo could not be identified in an epidemiologic study. Third, the status of smoking was obtained from self-reported questionnaires, raising the possibility of response bias. Fourth, the present study was cross-sectional, and therefore, the temporal relationship between smoking and vitiligo remains unclear. Fifth, the smoking status was obtained from questionnaires, which may be subject to recall bias. Sixth, the sample size was relatively small, which may have limited the statistical power of the study. Despite these limitations, our study provides valuable insights into the association between smoking and vitiligo, and further research is needed to clarify the underlying mechanisms and develop effective prevention and treatment strategies.
out. And the absence of data on time since quitting smoking in ex-smokers is considered as a limitation in this study. The role of smoking in vitiligo development remains for additional clinical analysis or in vitro studies.

Several strengths in this study are that first, we examined the relationship between vitiligo and smoking in the South Korean population. This study used a nation-wide population-based cohort. In Korea, a general health examination, either biannually or annually according to occupation, is mandatory for local household owners.

Figure 2. An adjusted cumulative incidence of vitiligo for baseline covariates including age, sex, regular exercise, drinking status, BMI, diabetes mellitus, hypertension, dyslipidemia, history of stroke, and history of myocardial infarction, according to smoking status.

| Subgroup | Smoking status | Number | Vitiligo | Person-years | Incidence rate (per 10,000 person-years) | HR(95% C.I.) |
|----------|----------------|--------|----------|--------------|------------------------------------------|--------------|
|          |                |        |          |              | Model 1 | Model 2 | Model 3 |
| Total    | Non            | 14,345,458 | 16,515 | 62,819,781.13 | 2.63 | 1(ref.) | 1(ref.) | 1(ref.) |
|          | Ex             | 3,042,684 | 3,003 | 13,438,871.66 | 2.23 | 0.83(0.79–0.86) | 1(0.95–1.05) | 1(0.95–1.05) |
|          | Current        | 5,603,499 | 3,293 | 24,374,473.09 | 1.35 | 0.56(0.54–0.59) | 0.68(0.64–0.71) | 0.69(0.65–0.72) |
| Male     | Non            | 3,615,580 | 3,399 | 16,007,707.47 | 2.12 | 1(ref.) | 1(ref.) | 1(ref.) |
|          | Ex             | 2,830,044 | 2,781 | 12,572,432.85 | 2.21 | 1.01(0.95–1.06) | 1(0.95–1.06) | 1(0.95–1.06) |
|          | Current        | 5,149,573 | 2,905 | 22,525,419.59 | 1.29 | 0.65(0.62–0.69) | 0.66(0.62–0.69) | 0.67(0.63–0.71) |
| Female   | Non            | 10,729,878 | 13,116 | 46,812,073.66 | 2.80 | 1(ref.) | 1(ref.) | 1(ref.) |
|          | Ex             | 212,640 | 222 | 866,438.81 | 2.56 | 1.03(0.89–1.19) | 1.03(0.89–1.18) | 1.03(0.89–1.18) |
|          | Current        | 453,926 | 388 | 1,849,053.5 | 2.10 | 0.79(0.71–0.88) | 0.79(0.71–0.88) | 0.79(0.7–0.88) |
| 20–39    | Non            | 3,684,294 | 2,860 | 15,877,168.48 | 1.80 | 1(ref.) | 1(ref.) | 1(ref.) |
|          | Ex             | 672,772 | 491 | 3,017,749.1 | 1.63 | 0.9(0.81–1) | 0.95(0.85–1.06) | 0.96(0.86–1.08) |
|          | Current        | 2,321,427 | 1,170 | 10,239,014.55 | 1.14 | 0.63(0.59–0.68) | 0.68(0.62–0.74) | 0.69(0.63–0.75) |
| 40–64    | Non            | 8,309,359 | 10,707 | 36,527,675.57 | 2.93 | 1(ref.) | 1(ref.) | 1(ref.) |
|          | Ex             | 1,903,257 | 1,952 | 8,411,829.96 | 2.32 | 0.78(0.74–0.82) | 1.01(0.94–1.07) | 1.01(0.95–1.08) |
|          | Current        | 2,888,057 | 1,818 | 12,483,012.69 | 1.46 | 0.52(0.5–0.55) | 0.67(0.63–0.71) | 0.67(0.63–0.71) |
| 65–      | Non            | 2,351,805 | 2,948 | 10,414,937.08 | 2.83 | 1(ref.) | 1(ref.) | 1(ref.) |
|          | Ex             | 466,655 | 560 | 2,009,292.61 | 2.79 | 0.96(0.87–1.05) | 1.1(0.98–1.23) | 1.1(0.98–1.24) |
|          | Current        | 384,015 | 305 | 1,652,445.85 | 1.85 | 0.63(0.56–0.71) | 0.71(0.62–0.82) | 0.75(0.65–0.86) |

Table 2. Incidence rates of vitiligo according to smoking status. Model 1 Not adjusted with setting an age timescale Model 2 Adjusted by baseline age and sex with setting an age timescale. Model 3 Adjusted by baseline age, sex, regular exercise, drinking status, BMI, diabetes mellitus, hypertension, dyslipidemia, history of stroke, and history of myocardial infarction with setting an age timescale. Hazard ratios for vitiligo development in ex-smokers and current smokers were obtained with reference to never-smokers. An age timescale was used in Model 1, 2, and 3. Subgroup analyses were evaluated by sex and age group.
office employees, and family members over the age of 40 years. The total number of individuals who underwent National Health Examinations in Korea from 2009 until 2012 was 23,503,802 that was more than half of the total population of Korea. Considering that we excluded subjects less than 20 years old, the results of this study could generalize the majority of Koreans who receive a medical examination. We identified the possible suppressive effects of smoking on the development of vitiligo. Current smokers showed a decreased risk of vitiligo development compared to non-smokers regardless of age and sex, and the amount of smoking was negatively correlated with vitiligo development. The suppressive mechanism of smoking on the cutaneous autoimmune disease, vitiligo, is unknown. Further *in vitro* studies are needed to investigate the exact mechanism between smoking and vitiligo. However, this study helps to broaden the understanding of vitiligo pathogenesis.

Received: 26 February 2019; Accepted: 18 March 2020; Published: xx xx xxxx

**References**

1. Ezzedine, K., Eleftheriadou, V., Whiton, M. & van Geel, N. Vitiligo. *Lancet* **386**, 74–84, [https://doi.org/10.1016/S0140-6736(14)60763-7](https://doi.org/10.1016/S0140-6736(14)60763-7) (2015).

2. Behl, P. N. & Bhatia, R. K. 400 cases of vitiligo. A clinico-therapeutic analysis. *Indian journal of dermatology* **17**, 51–56 (1972).

3. Canizares, O. Geographic dermatology: Mexico and Central America. The influence of geographic factors on skin diseases. *Arch Dermatol* **82**, 870–893 (1960).

4. Furue, M. *et al*. Prevalence of dermatological disorders in Japan: a nationwide, cross-sectional, seasonal, multicenter, hospital-based study. *The Journal of dermatology* **38**, 310–320, [https://doi.org/10.1111/j.1346-8138.2011.01209.x](https://doi.org/10.1111/j.1346-8138.2011.01209.x) (2011).

5. Howitz, J., Brodhagen, H., Schwartz, M. & Thomsen, K. Prevalence of vitiligo. Epidemiological survey on the Isle of Bornholm, Denmark. *Arch Dermatol* **113**, 47–52 (1977).

6. Lee, H. *et al*. Prevalence of vitiligo and associated comorbidities in Korea. *Yonsei medical journal* **56**, 719–725, [https://doi.org/10.3349/ymj.2015.56.3.719](https://doi.org/10.3349/ymj.2015.56.3.719) (2015).

| Amount of smoking | Number | Vitiligo | Person-years | Incidence rate per 10,000 person-years | HR(95%C.I) |
|-------------------|--------|----------|--------------|----------------------------------------|------------|
| Never-smoker      | 14,345,458 | 16,515 | 62,819,781.1 | 2.63 | 1(ref.) | 1(ref.) | 1(ref.) |
| Ex-smoker         |        |          |              |                                         |            |
| smoked <10 cigarettes/day | 475,960 | 472 | 2,056,674.1 | 2.29 | 0.87(0.80,0.96) | 1.04(0.95,1.14) | 1.03(0.94,1.13) |
| smoked 10–19 cigarettes/day | 1,160,814 | 1,124 | 5,173,202.4 | 2.17 | 0.83(0.78,0.88) | 1.01(0.95,1.08) | 1.01(0.95,1.11) |
| smoked ≥20 cigarettes/day | 1,405,910 | 1,407 | 6,208,995.1 | 2.27 | 0.86(0.82,0.91) | 1.01(0.95,1.08) | 1.03(0.97,1.10) |
| Current smoker    |        |          |              |                                         |            |
| smoked <10 cigarettes/day | 692,322 | 538 | 2,933,516.2 | 1.83 | 0.70(0.64,0.76) | 0.85(0.78,0.93) | 0.86(0.79,0.94) |
| smoked 10–19 cigarettes/day | 2,371,434 | 1,396 | 10,335,923.5 | 1.35 | 0.51(0.49,0.54) | 0.69(0.65,0.73) | 0.69(0.65,0.74) |
| smoked ≥20 cigarettes/day | 2,539,743 | 1,359 | 11,105,034.4 | 1.22 | 0.47(0.44,0.49) | 0.60(0.56,0.64) | 0.62(0.58,0.66) |

| Duration of smoking | Number | Vitiligo | Person-years | Incidence rate per 10,000 person-years | HR(95%C.I) |
|---------------------|--------|----------|--------------|----------------------------------------|------------|
| Never-smoker        | 14,345,458 | 16,515 | 62,819,781.1 | 2.63 | 1(ref.) | 1(ref.) | 1(ref.) |
| Ex-smoker           |        |          |              |                                         |            |
| smoked for <10 years | 708,297 | 635 | 3,093,384.6 | 2.04 | 0.78(0.72,0.84) | 1.02(0.94,1.11) | 1.02(0.94,1.11) |
| smoked for 10–30 years | 1,789,335 | 1,772 | 7,959,831.9 | 2.23 | 0.85(0.81,0.89) | 1.04(0.98,1.10) | 1.04(0.99,1.11) |
| smoked for ≥30 years | 545,052 | 596 | 2,374,378.6 | 2.51 | 0.96(0.88,1.04) | 0.99(0.90,1.07) | 0.98(0.90,1.07) |
| Current smoker      |        |          |              |                                         |            |
| smoked for <10 years | 891,176 | 521 | 3,778,089.1 | 1.38 | 0.52(0.48,0.57) | 0.77(0.71,0.85) | 0.79(0.72,0.87) |
| smoked for 10–30 years | 3,424,942 | 1,868 | 15,042,614.6 | 1.24 | 0.47(0.45,0.50) | 0.65(0.62,0.69) | 0.67(0.63,0.70) |
| smoked for ≥30 years | 1,287,381 | 904 | 5,553,769.4 | 1.63 | 0.62(0.58,0.66) | 0.67(0.63,0.72) | 0.68(0.63,0.73) |

Table 3. Hazard ratios of vitiligo development in association with amount and duration of smoking. Model 1 Not adjusted. Model 2 Adjusted by age and sex. Model 3 Adjusted by age, sex, regular exercise, drinking status, BMI, diabetes mellitus, hypertension, dyslipidemia, history of stroke, and history of myocardial infarction.

| Detrimental | Protective |
|------------|-----------|
| Palmoplantar pustulosis | Pemphigus vulgaris |
| Psoriasis | Aphthous ulcer |
| Hidradenitis suppurativa | Oral ulcer in Behçet's disease |
| Systemic lupus erythematosus | Wound healing |
| | Skin aging |

Table 4. Effects of smoking on skin disease.
59. Lee, P. C.
61. Berkowitz, L.
68. Schallreuter, K. U.
65. Laddha, N. C.
62. Sari, Y. & Khalil, A. Monoamine Oxidase Inhibitors Extracted from Tobacco Smoke as Neuroprotective Factors for Potential
64. Malczewska-Jaskola, K., Jasiewicz, B. & Mrowczynska, L. Nicotine alkaloids as antioxidant and potential protective agents against
63. Gallo, V.
50. Chattopadhyay, A. & Chatterjee, S. Risk indicators for recurrent aphthous ulcers among adults in the US.
51. Ciancio, G.
49. Shapiro, S., Olson, D. L. & Chellemi, S. J. The association between smoking and aphthous ulcers.
48. Tuzun, B., Wolf, R., Tuzun, Y. & Serdaroglu, S. Recurrent aphthous stomatitis and smoking. *Int J Dermatol* 39, 358–360 (2000).
47. Shapiro, S., Olson, D. L. & Chellemi, S. J. The association between smoking and aphthous ulcers. *Oral Surg Oral Med Oral Pathol* 30, 624–630 (1970).
50. Chatthopadhyay, A. & Chatterjee, S. Risk indicators for recurrent aphthous ulcers among adults in the US. *Community Dent Oral Epidemiol* 35, 152–159, https://doi.org/10.1111/1600-0528.2007.00329.x (2007).
51. Ciancio, G. et al. Nicotine-patch therapy on mucocutaneous lesions of Behcet's disease: a case series. *Rheumatology (Oxford)* 49, 501–504, https://doi.org/10.1093/rheumatology/kep401 (2010).
52. Kalayciyan, A. et al. Nicotine and biochanin A, but not cigarette smoke, induce anti-inflammatory effects on keratinocytes and endothelial cells in patients with Behcet's disease. *The Journal of investigative dermatology* 127, 81–89, https://doi.org/10.1016/j.jid.2007.05.006 (2007).
53. Kaklamani, V. G., Markomichealis, N. & Kaklamanis, P. G. Could nicotine be beneficial for Behcet's disease? *Clin Rheumatol* 21, 341–342 (2002).
54. Rizvi, S. W. & McGrath, H. Jr. The therapeutic effect of cigarette smoking on oral/genital aphthosis and other manifestations of Behcet’s disease. *Clin Exp Rheumatol* 19, S77–78 (2001).
55. Malek Mahdavi, A. et al. Cigarette smoking and risk of Behcet’s disease: a propensity score matching analysis. *Mod Rheumatol*, 1–7, https://doi.org/10.1080/14997995.2018.1493066 (2018).
56. Aramaki, K., Kikuchi, H. & Hirohata, S. HLA-B51 and cigarette smoking as risk factors for chronic progressive neurological manifestations in Behcet's disease. *Mod Rheumatol* 17, 81–82, https://doi.org/10.1007/s10165-006-0541-z (2007).
57. Ozer, H. T. et al. The impact of smoking on clinical features of Behcet's disease patients with gluthathione S-transferase polymorphisms. *Clin Exp Rheumatol* 30, S14–17 (2012).
58. Gallo, V. et al. Exploring causality of the association between smoking and Parkinson's disease. *Int J Epidemiol*, https://doi.org/10.1093/ije/dyv230 (2018).
59. Lee, P. C. et al. Smoking and Parkinson disease: Evidence for gene-by-smoking interactions. *Neurology* 90, e583–e592, https://doi.org/10.1212/WN1.0000000000004953 (2018).
60. Aronsohn, Y., Shoenfeld, Y. & Amital, H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. *J Autoimmun* 34, J258–265, https://doi.org/10.1016/j.jaut.2009.12.003 (2010).
61. Berkowitz, L. et al. Impact of Cigarette Smoking on the Gastrointestinal Tract Inflammation: Opposing Effects in Crohn’s Disease and Ulcerative Colitis. *Front Immunol* 9, 74, https://doi.org/10.3389/fimmu.2018.00074 (2018).
62. Sari, Y. & Khalil, A. Monoamine Oxidase Inhibitors Extracted from Tobacco Smoke as Neuroprotective Factors for Potential Treatment of Parkinson’s Disease. *CNS Neurol Disord Drug Targets* 14, 777–785 (2015).
63. Leroy, C. et al. Cerebral monoamine oxidase A inhibition in tobacco smokers confirmed with PET and [11C]befloxatone. *J Clin Psychopharmacol* 29, 86–88, https://doi.org/10.1097/JCP.0b013e318199e8f (2009).
64. Malczewska-Jaskola, K., Jasiewicz, B. & Mrowczynska, L. Nicotine alkaloids as antioxidant and potential protective agents against in vitro oxidative haemolysis. *Chem Biol Interact* 243, 62–71, https://doi.org/10.1016/j.cbii.2015.11.030 (2016).
65. Laddha, N. C. et al. Role of oxidative stress and autoimmunity in onset and progression of vitiligo. *Exp Dermatol* 23, 352–353, https://doi.org/10.1111/exd.12372 (2014).
66. Schaller, K. U. et al. In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. *J Invest Dermatol Symp Proc* 4, 91–96 (1999).
67. Hann, S. K., Chang, J. H., Lee, H. S. & Kim, S. M. The classification of segmental vitiligo on the face. *Yonsei medical journal* 41, 209–212, https://doi.org/10.3349/ymj.2000.41.2.209 (2000).
68. Schaller, K. U. et al. Increased monoamine oxidase A activity in the epidermis of patients with vitiligo. *Arch Dermatol Res* 288, 14–18 (1996).
69. Zedan, H., Abdel-Motaleb, A. A., Kassem, N. M., Hafez, H. A. & Hussein, M. R. Low glutathione peroxide activity levels in patients with vitiligo. *J Cutan Med Surg* 19, 144–148, https://doi.org/10.1038/s41598-020-63384-y (2020).
70. Sravanvi, P. V. et al. Determination of oxidative stress in vitiligo by measuring superoxide dismutase and catalase levels in vitiliginous and non-vitiliginous skin. *Indian J Dermatol Venereol Leprol* 75, 268–271, https://doi.org/10.4103/0378-6323.48427 (2009).

**Acknowledgements**

This study was supported by a National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (NRF-2019R1F1A1056601). This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (NRF-2019R1F1A1056601). IRB approval status: Reviewed and approved by the Institutional Review Board at Uijeongbu St. Mary's Hospital, Catholic University of Korea (UC18ZEISI0095)

**Author contributions**

Young Bok Lee, Ji Hyun Lee, and Yong Gyu Park participated in designing the study. Kyung Do Han and Yong Gyu Park participated in generating and gathering the data for the study. Young Bok Lee, Ji Hyun Lee, Soo Young Lee, Dong Soo Yu, Kyung Do Han, and Yong Gyu Park participated in the analysis of the data. All authors participated in writing the paper. All authors reviewed and approved all versions of the manuscript.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Correspondence** and requests for materials should be addressed to J.H.L. or Y.G.P.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
